Indianapolis, Indiana, United States, 46250 Tampa, Florida, United States, 33613-1244Įvansville, Indiana, United States, 47715ĭawes Fretzin Clinical Research Group, LLC Miami, Florida, United States, 33165 3338 San Francisco, California, United States, 94119īridgeport, Connecticut, United States, 06606įlorida Academic Centers Research and Education, LLCĬoral Gables, Florida, United States, 33134 Northridge, California, United States, 91324

Scottsdale, Arizona, United States, 85255įountain Valley, California, United States, 92708Ĭenter For Dermatology Clinical Research, Inc.įremont, California, United States, 94538 Total Skin and Beauty Dermatology Center, PCīirmingham, Alabama, United States, 35205

Previously treated with an oral Janus kinase (JAK) inhibitor and had an inadequate response (for example, absence of significant terminal hair growth after at least 12 weeks of treatment).Are currently experiencing other forms of alopecia or any other concomitant conditions that would interfere with evaluations of the effect of study medication on AA.Male or nonpregnant, nonbreastfeeding female participants.Note: participants who have severe or very severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years. Current episode of severe or very severe AA of less than 8 years.No spontaneous improvement over the past 6 months.Current AA episode of more than 6 months' duration and hair loss encompassing ≥50% of the scalp, as measured by SALT (AA-IGA of 3 or 4) at screening and baseline.Have severe or very severe AA, as determined by all of the following: Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent.Why Should I Register and Submit Results?.

Brave 2 2021